Immunotherapy in All Aspects

Overview

Journal Eur Arch Otorhinolaryngol

Specialty Otorhinolaryngology

Date 2015 Feb 13

PMID 25673026

Citations 5

Authors

Deniz Hanci

Ethem Sahin

Nuray Bayar Muluk

Cemal Cingi

Affiliations

Soon will be listed here.

Abstract

Allergen immunotherapy is a form of long-term treatment that decreases symptoms for many people with allergic rhinitis, allergic asthma, conjunctivitis (eye allergy) or stinging insect allergy. In this review, we presented the important topics in immunotherapy. The important aspects of immunotherapy are considered to be "Immunologıcal responses to immunotherapy"; "The principal types of immunotherapy"; "Effectiveness"; "Indications"; "Contraindications"; "Allergen immunotherapy in children"; "Safety"; and "Anaphylactic reactions after immunotherapy". The principal types of immunotherapy are subcutaneous immunotherapy (SCIT) and sublingual immunotherapy. Both of them can be used in indicated cases. When using SCIT, physicians must be more careful because of reported rare fatal cases. The risks and benefits of continuing allergen immunotherapy in patients who have experienced severe systemic reactions should be carefully considered.

Citing Articles

Bibliometric and visual analysis in the field of two-dimensions nano black phosphorus in cancer from 2015 to 2023.

Huang J, Zhang L, Li B, Lian Y, Lin X, Li Z Discov Oncol. 2024; 15(1):260.

PMID: 38961044 PMC: 11222346. DOI: 10.1007/s12672-024-01104-y.

Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review.

Ding R, Jiao H, Piao Y, Tian W Medicine (Baltimore). 2023; 102(39):e35506.

PMID: 37773801 PMC: 10545358. DOI: 10.1097/MD.0000000000035506.

Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).

Ecevit M, Ozcan M, Haberal Can I, Tatar E, Ozer S, Esen E Turk Arch Otorhinolaryngol. 2021; 59(Suppl 1):1-157.

PMID: 34212158 PMC: 8221269. DOI: 10.4274/tao.2021.suppl.1.

[Effect of sublingual immunotherapy with Dermatophagoides Farinae on the expression of specific IgG4 in patients with allergic rhinitis in Hainan area].

Huang Q, Wei X, Lin X, Zheng J, Huang H Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020; 34(2):135-139.

PMID: 32086918 PMC: 10128420. DOI: 10.13201/j.issn.1001-1781.2020.02.009.

Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children.

Tsabouri S, Mavroudi A, Feketea G, Guibas G Front Pediatr. 2017; 5:82.

PMID: 28484690 PMC: 5399038. DOI: 10.3389/fped.2017.00082.

References

Maestrelli P, Zanolla L, Pozzan M, Fabbri L . Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol. 2004; 113(4):643-9. DOI: 10.1016/j.jaci.2003.12.586. View

Dunsky E, Goldstein M, Dvorin D, Belecanech G . Anaphylaxis to sublingual immunotherapy. Allergy. 2006; 61(10):1235. DOI: 10.1111/j.1398-9995.2006.01137.x. View

Scadding G, Durham S . Mechanisms of sublingual immunotherapy. J Asthma. 2009; 46(4):322-34. DOI: 10.1080/02770900902785729. View

Bernstein D, Wanner M, Borish L, Liss G . Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. 2004; 113(6):1129-36. DOI: 10.1016/j.jaci.2004.02.006. View

Alvarez-Cuesta E, Bousquet J, Canonica W, Durham S, Malling H, Passalacqua G . Reply to the letter by Dr Fleming Madsen (EAACI 'Standards for practical allergen-specific immunotherapy'). Allergy. 2008; 63(7):939-40. DOI: 10.1111/j.1398-9995.2008.01648.x. View

Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G . Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006; 97(2):141-8. DOI: 10.1016/S1081-1206(10)60004-X. View

Frew A, Powell R, Corrigan C, Durham S . Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006; 117(2):319-25. DOI: 10.1016/j.jaci.2005.11.014. View

Varney V, Hamid Q, Gaga M, Ying S, Jacobson M, Frew A . Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. 1993; 92(2):644-51. PMC: 294897. DOI: 10.1172/JCI116633. View

Furin M, Norman P, Creticos P, Proud D, Lichtenstein L, Naclerio R . Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol. 1991; 88(1):27-32. DOI: 10.1016/0091-6749(91)90297-2. View

10.

Lockey R, Theodoropoulos D, BUKANTZ S . Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol. 2001; 87(1 Suppl 1):47-55. DOI: 10.1016/s1081-1206(10)62195-3. View

11.

Ibanez M, Kaiser F, Knecht R, Armentia A, Schopfer H, Tholstrup B . Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol. 2007; 18(6):516-22. DOI: 10.1111/j.1399-3038.2007.00556.x. View

12.

Nielsen L, Johnsen C, Mosbech H, Poulsen L, Malling H . Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol. 1996; 97(6):1207-13. DOI: 10.1016/s0091-6749(96)70186-0. View

13.

Moller C, Dreborg S, Lanner A, Bjorksten B . Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy. 1986; 41(4):271-9. DOI: 10.1111/j.1398-9995.1986.tb02028.x. View

14.

Peroni D, Piacentini G, Martinati L, Warner J, Boner A . Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude. Allergy. 1995; 50(11):925-30. DOI: 10.1111/j.1398-9995.1995.tb02500.x. View

15.

Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O . Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005; 116(3):608-13. DOI: 10.1016/j.jaci.2005.06.004. View

16.

Kivity S, Yarchovsky J . Relapsing anaphylaxis to bee sting in a patient treated with beta-blocker and Ca blocker. J Allergy Clin Immunol. 1990; 85(3):669-70. DOI: 10.1016/0091-6749(90)90111-g. View

17.

Fujimura T, Yonekura S, Taniguchi Y, Horiguchi S, Saito A, Yasueda H . The induced regulatory T cell level, defined as the proportion of IL-10(+)Foxp3(+) cells among CD25(+)CD4(+) leukocytes, is a potential therapeutic biomarker for sublingual immunotherapy: a preliminary report. Int Arch Allergy Immunol. 2010; 153(4):378-87. DOI: 10.1159/000316349. View

18.

Francis J, James L, Paraskevopoulos G, Wong C, Calderon M, Durham S . Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol. 2008; 121(5):1120-1125.e2. DOI: 10.1016/j.jaci.2008.01.072. View

19.

Cox L, Linnemann D, Nolte H, Weldon D, Finegold I, Nelson H . Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006; 117(5):1021-35. DOI: 10.1016/j.jaci.2006.02.040. View

20.

Fujimura T, Yonekura S, Horiguchi S, Taniguchi Y, Saito A, Yasueda H . Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. Clin Immunol. 2011; 139(1):65-74. DOI: 10.1016/j.clim.2010.12.022. View